Brief Report: Transgender Women and Preexposure Prophylaxis Care: High Preexposure Prophylaxis Adherence in a Real-World Health Care Setting in New York City. (1st May 2022)

• Record Type: Journal Article
• Authors: Starbuck, Lila; Golub, Sarit A.; Klein, Augustus; Harris, Alexander B.; Guerra, Amiyah; Rincon, Christopher; Radix, Asa E.
• Is Part Of: Journal of acquired immune deficiency syndromes. Volume 90:Number 1(2022)
• Page Start: 15
• Page End: 19
• Publication Date: 2022-05-01
• Subjects: HIV -- preexposure prophylaxis (PrEP) -- implementation science -- transgender women -- transgender -- medication adherence; AIDS (Disease) -- Periodicals; Acquired Immunodeficiency Syndrome -- Periodicals; AIDS (Disease); Periodicals; 616.9792005
• DOI: 10.1097/QAI.0000000000002915
• Languages: English
• ISSNs: 1525-4135

Abstract

Abstract : Background: Transgender women and trans feminine individuals (TGW/TFI) are a high priority population for the provision of HIV preexposure prophylaxis (PrEP) care within the United States, but there is limited research that focuses specifically on PrEP adherence within this population. Setting: Observational study of patients prescribed PrEP at a community-based health center. Methods: We enrolled 100 TGW/TFI PrEP patients at a community health center during clinic visits. Adherence data were collected at 3 time points, using self-report surveys, patient interviews, and urine assays measuring tenofovir. Data were summarized descriptively. Results: The sample was diverse in age, race/ethnicity, and socioeconomic characteristics. Participants demonstrated strong PrEP adherence; at least 80% of the sample reported 90% or greater adherence at each time point. Concordance between self-report and urine assay was high. Among patients who reported taking PrEP within the past 48 hours, 82%–92% had detectable urine tenofovir. However, many patients reported PrEP stop periods of 4 or more days (28%–39% per time point). Conclusions: Our data highlight TGW/TFI's capacity to adhere to daily PrEP and sustain PrEP use over time. The concordance between patient self-report and urine TFV levels suggest that providers can trust patient reports of PrEP adherence behavior and support the use of adherence conversations in clinical settings, without the need for point of care biological monitoring. Findings also underscore the importance of continued attention to drivers of PrEP stops at the patient, clinic, and systems levels and the development of strategies that support sustained PrEP use.